


Registered number: 04509293
Charity numbers: 1094231 & SC039257

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report and financial statements

For the year ended 31 March 2023

TUESDAY



ACHPSSTD

A05

05/12/2023

#109

COMPANIES HOUSE

The British Allergy Foundation
(A company limited by guarantee)

Contents

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 14
Independent auditors' report on the financial statements	15 - 19
Consolidated statement of financial activities	20
Consolidated balance sheet	21
Charity balance sheet	22
Consolidated statement of cash flows	23
Notes to the financial statements	24 - 50

The British Allergy Foundation
(A company limited by guarantee)

Reference and administrative details of the Charity, its Trustees and advisers
For the year ended 31 March 2023

Trustees

Ms L Pritchard, Chair
Mrs A Tharani, Vice Chair
Mr R Daby
Mr R Dudley-Southern MBE
Mr P Frampton (appointed 29 September 2022)
Dr B Hewitt
Mr J Redding (resigned 24 November 2022)
Dr G Stjefel
Dr S Kayode (appointed 24 November 2022)
Ms R Oldroyd (appointed 23 February 2023)
Ms K Sykes (appointed 17 June 2023)
Ms E Withers (appointed 24 November 2022)

Company registered number 04509293

Charity registered numbers 1094231 and SC039257

Registered office London House Business Centre
Thames Road
Crayford
Dartford
England
DA1 4SL

Company secretary P Turnbull

Chief executive officer S Miles

Independent auditors Kreston Reeves LLP
Chartered Accountants
Statutory Auditor
37 St Margaret's Street
Canterbury
Kent
CT1 2TU

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report
For the year ended 31 March 2023

The Trustees present their annual report together with the audited financial statements of the Charity for the 1 April 2022 to 31 March 2023. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the group and the Charity qualify as small under section 383 of the Companies Act 2006, the Group strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

The group and the Charity also trade under the name Allergy UK.

Objectives and activities

a. Policies and objectives

The Charitable Objects for the charity are:

- 3.1 To raise public awareness around allergy and the causes of anaphylaxis.
- 3.2 To produce reliable information and education in the community for the management and prevention of all allergic reactions, including anaphylaxis.
- 3.3 To provide support in the community to all those affected by allergy, covering all manifestations of allergy to reduce risk of serious allergic reaction (anaphylaxis). This support extends to bereaved families.
- 3.4 To promote research into the cause and care for all allergic conditions, including those that cause anaphylaxis, in order to improve health and quality of life for people living with allergy and associated diseases.
- 3.5 To increase the profile of and advocacy for all allergic conditions, including the seriousness of anaphylaxis, providing advice and representation to government, industry, and other organisations, and being a conduit for information and research for a range of expert and patient stakeholders.
- 3.6 To campaign for policy and legislative changes to improve the lives of all people living with allergy, including those who live with the risk of anaphylaxis.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

Achievements and performance

a. Main achievements of the Charity

In 2022/23 we continued to work towards our strategic objectives as set out in our Strategy for Change 2020-2025 plans.

We are delighted to share with you the Allergy UK Impact Report for 2022-23 which showcases the work that we have undertaken over the last year to ensure we continue to provide support and services to those living with allergic disease across the UK. The report is available to be viewed digitally on our website via the link below, with a summary of key achievements mentioned here in this report.

<https://www.allergyuk.org/resources/allergy-uk-impact-report-2022-23/>

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Achievements and performance (continued)

Research – Understanding Allergy

Patient Charter for People Living with Allergic Disease

Allergy UK's research is used to inform services we provide, public affairs campaigns we lobby on behalf of the allergic community, and the strategic approach of the charity. Our real-world evidence survey and focus groups in 2021 led to a collaboration between patients, carers, clinicians and Allergy UK and the development of a Patient Charter for People Living with Allergic Disease. This Charter was launched at Westminster in May 2022 with the key vision of:

- A right to a quality standard of care: for everyone living with allergy throughout the UK
- A right to accurate information and education: Empowerment of patients with allergic conditions to understand and manage their condition with support from informed healthcare professionals
- A right to equality in society: Promotion of a better awareness and understanding of allergy so that people with allergic conditions are not discriminated against in any aspect of their daily lives.

The findings informed the development of Allergy UK's new long-term campaign which launched in April 2022. The aim of the campaign is to raise awareness of the challenges associated with living with an allergy, across the whole spectrum of allergic conditions. It also seeks to shift public perceptions on allergies and the needs of those who live with an allergy.

As a part of our campaign, we are advocating for primary care to have specialist allergy nurses and dietitians in every Integrated Care Board (ICB). ICBs are now responsible for commissioning allergy services at a local level (which are not specialist services) and Allergy UK sent out a Freedom of Information request to all 42 ICBs in March 2023.

We are using the results of the Allergy UK funded research of a nurse-led allergy clinic, published in 2022 to support this campaign. Of those referred into the service 90% of healthcare professionals stated that they would have referred the patient into secondary care, had the clinic not been available. Incidentally, after being seen in the nurse led clinic, only 5% of these patients required to be referred onto to a secondary care service. The project ran between 2017-2021 and the results were published August 2022 in Clinical and Translational Allergy: <https://onlinelibrary.wiley.com/doi/full/10.1002/ctt2.12180> showing improved patient pathways and cost efficiencies.

Alongside this, we are re-visiting the evaluation of Allergy UK's Dietitian Service to gather current data on the impact this service has made to families who have used it. Over 1600 infants have been referred through this service since its inception in 2015 and many have been seen to have gone on to receive a diagnosis of food allergy. Previous evaluation highlighted the positive impact of this service for families and support from GPs for the service.

Empowering – supporting and informing through our Helpline and resources

Our Helpline continued to provide essential information and support for the allergic community throughout 2022/23 with a 12.6% increase in calls from last year. Many callers are anxious about their allergies, or suspected allergies and the Helpline has received a lot of calls about the emotional impact of living with this disease. Feedback from those who use our services shows us they appreciate the advice and care received as they often cannot seem to access other support.

Allergy UK is the only allergy charity with in-house clinical experts in allergy. 180 calls to our Helpline required specialist support from our in-house Allergy Nurses, with 48 calls needed advice on eczema provided by our Allergy Nurses. This has highlighted a need to develop this eczema service in 2022/23 as a bespoke service. We wish to thank our Health Advisory Board and our clinical Trustees for their expertise and constant support for all calls to our Helpline.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Achievements and performance (continued)

Our Dietitian Service has now supported over 1600 children in a 5-year period where parents call, often in desperation, as they have been unable to have their concerns about their child's suspected food allergy listened to or are unable to access someone with the expertise. 320 children were supported through our Dietitian services this year, and we hope this service will be sustainable with continued grants and sponsorship.

Over the last year, the youth engagement program has invited young people to participate in activities with Allergy UK to share their stories of living with allergy, raise awareness of allergy and gain peer to peer support with an average of 12 to 30 young people getting involved in the activities. In August 2022, the young people met face to face in London whereby they were able to participate in fun activities and plan the main activity to create a film over the next 6 months. The film will be completed in the summer of 2023. Since the recruitment of a part-time volunteer coordinator in 2022, the volunteering programme has welcomed 17 volunteers to participate in a variety of roles from fundraising, event management, lay review and project management. Volunteers have made a real impact by supporting us to implement a project management system, coordinate and run an event in April 2023 and fundraising at Christmas.

Educating – improving awareness, knowledge, and skills in allergy

Our educational resources support patients, carers, and non-specialist healthcare professionals in developing knowledge of allergic disease and in 2022/23 we developed many excellent additional resources to provide advice and information for people living with allergy. Our parent pathways digital resource aimed at parents and carers who are living with allergy, takes them on a journey through each stage of transition with useful support tools and tips to manage this often stressful time. We also created resources for managing asthma, adrenaline autoinjectors, cows milk allergy and house dust mite. The resources reached both people living with allergy and the healthcare professional supporting them. The resources include factsheets, podcasts and videos. In total we issued 12 new resources. Our popular masterclass programme for healthcare professionals continued to grow in 2022, bringing together primary care practitioners to learn directly from experts in the field of allergy. We delivered 7 masterclasses with 1,600 registrations. Our resources are also well received by healthcare professionals with 1,322 downloads during 2022/23.

Influencing – connecting with key stakeholders

Our forward focus is on our campaign "It's time to take allergy seriously", engaging with key influencers and stakeholders to raise awareness of the needs of people living with allergy to influence change and equality for all living with this complex disease.

In August 2022 we re-contracted a public affairs company, Connect, for a further year and through this connection we have met with many more MPs and Peers to discuss the needs of the allergic community. This engagement focus with key decision makers will continue into future years as a key part of our campaigning, and to date has enabled us to secure a number of Allergy Champions. We have also work with Connect to support the All-Party Parliamentary Group on Allergy Chair, Jon Cruddas MP, lead a Parliamentary back-bench debate on allergy awareness in Westminster in May 2023. We have also attended a Westminster Hall debate on a national lead for allergy and food labelling on menus.

Allergy UK is a part of the National Allergy Strategy Group, which provides the Secretariat for the All-Party-Parliamentary Group for Allergy, and in October 2021 patient representatives delivered a report to the then Minister for Care and Mental Health, Gillian Keegan MP, which outlined the continued un-met need of allergy services across the UK. This meeting has led to several meetings, which have been on-going in 2022 and 2023 with the Department of Health and Social Care Long Term Conditions team. Allergy UK is a core representative for patients at these meetings where the NASG are proposing the establishment of an expert advisory group to support a National Allergy Strategy, which can inform policy development on areas which impact on living with allergy.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Achievements and performance (continued)

We very much appreciate the support that our Parliamentary Allergy Champions are providing, alongside those other MPs and their Officers who have expressed support for our campaign and attended our Parliamentary event in May 2022 for the launch of the Patient Charter and have supported debates and discussions. This work will continue into 2023 and beyond, with decision-makers across the UK.

Allergy UK also plays a key influencing role at a UK level with involvement in:

- the National Allergy Strategy Group,
 - the steering group of the Children and Young People's Allergy Network in Scotland (CYANS)
 - the Patient and Public Voice partner for NHS England's Specialised Commissioning Clinical Reference Group for Immunology and Allergy Services
 - represents patient perspectives when asked by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute of Clinical Excellence (NICE)
 - a member of the Royal College of Physicians' Improving Quality in Allergy Services (IQAS) accreditation steering group
 - is a patient representative in many of the British Society for Allergy and Clinical Immunology (BSACI) activities
 - has regular meetings with the Food Standards Agency (FSA) and is a contact for the Food Standards Scotland (FSS)
- Allergy UK also plays a key influencing role at a UK level with involvement in:

At a European and global level Allergy UK's influence is in collaboration with other peer organisations. Our Chief Executive was voted President of the European Federation of Allergy and Airways' Diseases' Patient Organisations' Association (EFA) in 2021 by our European peer organisations. This is a two-year post, as Allergy UK has held a place on the EFA Board for 4 years to date, and the CEO stepped down as President of EFA in April 2023. In addition, Allergy UK held the Co-Chair position of the European Academy of Allergy and Clinical Immunology Patient Organisation Committee until October 2023, after three and a half years supporting global patient organisations in this role. The charity is also a member of Global Skin, and the Global Allergy and Asthma Patient Platform (GAAPP). All these collaborations work to raise awareness of the issues faced, seeking to influence policy and social changes to improve equality and quality of life for people living with allergies.

b. Fundraising activities and income generation

Allergy UK is registered with and has paid the Levy required by the Fundraising Regulator. The Charity is a member of the Institute of Fundraising and complies with all required regulations, including ensuring all procedures comply with General Data Protection Regulations, thereby protecting the data of all who contact the Charity. We are pleased to advise that we have not received any complaints relating to fundraising during this year.

One of our key goals is to strengthen our income generation capability to safeguard the long-term future of the Charity. Currently every £1 we raise provides 53 pence to deliver our services and our objective is to increase this contribution, but this is reliant on unrestricted income and grants to support core services.

We have four principal revenue streams, including income received via the charity's trading subsidiary Allergy Research Limited.

Community Fundraising: In 2022 we recruited a Head of Fundraising and a Senior Fundraising Officer, both of whom have begun to make a real impact on managing and developing plans for our fundraising income streams. This has been essential to providing support for those individuals and companies who are generously committed to donating and raising funds to for our charity and for allergic disease.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Achievements and performance (continued)

Judith's Wish was the Christmas 2022 fundraising campaign. The campaign's key objectives were to educate people about the dangers of severe food allergies, highlight the need to improve the labelling of food and drink products and to raise much-needed funding for Allergy UK. Judith's Wish was disseminated digitally to 24,000 people (whose lives have been affected by allergies) across the UK in November 2022. A further 3,000 copies of the campaign leaflet were distributed to the public in England, whilst an additional 1,000 copies were issued in South Wales. It was a great year for Community Fundraising, with Allergy UK being fortunate enough to secure High Street presence for collections. Donations were made and over 1,000 copies of our Judith's Wish campaign leaflets distributed. To date, Judith's Wish has received donations exceeding our target by over 11%. We were also fortunate to receive the support of five local businesses who gave in kind donations for the campaign. In 2023/24, our Christmas Campaign aims to grow its reach by a further 10% and increase its the amount of money raised by an additional 20%.

London Knightz continues to offer their ongoing support to the cause and have held two raffles and a hockey tournament in 2022, in aid of Ruben's memory. Allergy UK would like to extend our most sincere and heartfelt thanks to the Bousquet family, The London Knightz and all those who have so generously supported us over the past year.

Allergy UK is extremely grateful to all of our supporters and those who have donated through fundraising, donating to appeals, legacies and other ways, as despite the continued difficulties from the economic impact our supporters did increase individual giving donations during 2022, enabling us to deliver services for all living with allergy in the UK. Without these donations and support our work would not be possible.

Trust Fundraising: It remains very challenging to secure funds despite contacting an external company to complete and submit bids.

However, we would like to thank Pilkington Trust for their continued support with grants, receiving £5,000 which we very much appreciate. Other grants received were Novartis Pharmaceuticals for £6,195 so that Allergy UK were able to raise awareness of Chronic Spontaneous Urticaria, a condition often mistaken for allergy as it presents like an allergy. No other organisation in the UK supports this condition. We also thank Global skin for \$2,400 CAD to raise awareness of eczema on World Eczema Day. Nutrica £4,680 to enable Allergy UK to be represented at the British Society of Allergy & Clinical Immunology, Aimmune £5,529 for resources to support people living with the psychological impact of food allergy, Pfizer £9,466 to support both Healthcare professionals and people with skin allergy with resources, and Sanofi £77,853 for a youth engagement project, parent and carer support and skin resources.

Corporate Partnerships and Sponsorship: Most sponsorships were received from corporate partners, and we would like to express our thanks and gratitude to all companies who continue to support Allergy UK, year on year as their support is essential to our sustainability, whether this be through a grant, or sponsorship of projects through our trading subsidiary, Allergy Research Limited.

In 2022 we had 16 established corporate partners, which has enabled Allergy UK to continue to deliver some key services, such as our Dietitian Service, provide free Masterclasses for healthcare professionals, and develop resources on allergic disease. Corporate partner support has also enabled us to launch our Youth Engagement Programme in 2022.

Those who supported projects and activities that took place in 2022 are also listed in our Impact Report, and we wish to thank Abbott, Abbvie, Aimmune, ALK, +ecohydra, Nutricia, Pfizer, Poti, Robert Thomas, Sanofi, Sealy, Novartis, Naroo.

Endorsements and Licensing: Our trading subsidiary Allergy Research Limited provides endorsements for products which may provide support for the symptoms experienced by people living with allergy. The company donates all profits to Allergy UK each year enabling the charity to utilise these unrestricted funds for operational and other costs.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Achievements and performance (continued)

All donated income from the trading subsidiary directly finances the charity's expenditure on operational activities and staffing resources. Operational expenditure provides a helpline; the funding of a communications team to promote awareness of allergic diseases; the employment of three allergy nurses and a dietitian to support the helpline and provide subject matter expertise on allergy and immunology; a team supporting the trading activities and involvement with other organisations with the similar focus on areas of allergic disease. All surpluses will be used to finance future charitable expenditure, either for ongoing activities, or one-off projects.

The trading subsidiary provides the Charity's principal funding source and continued to perform well despite the difficult global economic conditions. Both its major activities (operation of endorsement programmes and working with corporate partners) exceeded expectations for the year, the budget for which had remained conservative when considering the economic forecasts. Our trading subsidiary activities are all aimed to be of benefit towards achieving the Charity's aims to provide support for those living with allergy and raise awareness of allergic disease.

Cash flow has been closely monitored throughout the year and all outflows are planned and well within the Charity's resources. However, in 2023/24 we will be reviewing how much of our reserves we hold in fixed term accounts to ensure cash flow is not affected.

The activities carried out by the Charity's subsidiary, Allergy Research Limited, require higher costs compared to a charity which only seeks public donations. The endorsement scheme independently tests applicants' products using specialist laboratories at commensurate fees. Allergy Research Limited activities involve delivering projects, which are supported by sponsorship from our corporate partners. These projects are aimed at increasing public and healthcare professional knowledge and awareness of allergy issues. The endorsement schemes and projects incur costs to enable the achievement of outcomes and many of them are now delivered through digital solutions for which the Charity utilises third party providers. These costs are covered using donated contributions from our corporate partners and any surplus funds designated for this purpose. The majority of the Charity's income is generated, via the subsidiary, by these two means.

Financial review

a. Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

b. Reserves policy

The Board of Trustees reviewed the reserves policy in accordance with the charity's strategic planning, operational decisions, budgeting and risk management processes. At every Board meeting, the Trustees can see the movement in reserves and, therefore, are aware of the level of reserves held by the charity. In addition, the reserves position is usually formally reviewed twice a year in February and September.

Financial risk management for the group includes ensuring that there is sufficient contingency reserve to enable the group to respond to an unforeseen event or emergency. The Trustees provide the CEO with the authority to make financial decisions relating to operational need, providing there are three to four months contingency reserves available. This is revisited every 6 months to ensure good financial practice. It is Allergy UK's policy that any financial decision that would result in reducing the contingency reserves to under four months of the charity's operational costs would have to be escalated to the Board of Trustees for a decision.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

The charity receives a steady income stream from its trading subsidiary, and it is considered highly unlikely that this would cease immediately. It is assumed that, for the purpose of setting the reserves level, income must be set at a level which is equal to or exceeds expenses. There could, however, be a steady or sudden reduction in income arising from events outside of Allergy UK's control and sufficient reserves should therefore be held to cover a stressed drop in income over a period of six months. This would give management time to take action to reduce headcount/costs to match the lower levels of income.

The average monthly income for the group in 2022/23 was £152,070 and is currently £130,000 (February 2023), which excludes legacy income. A stressed reduction rate of 10% per month has been applied to calculating the reserve requirement. The Trustees have set a minimum reserves requirement at three months of current average income (£390,000) to cover a potential 10% stressed reduction in income over a six-month period. The balance on the contingency reserve at 31 March 2023 was £466,220.

The contingency reserve must be held on deposit accounts at a mix of terms and maturity dates, but not exceeding 12 months, to enable the funds to be accessed when required.

The Trustees expect management to maintain a reserve cushion at least equal to the four-month minimum and must be notified immediately of any events or expenditure that might cause the reserves to fall below that level. The charity will always seek to utilise funds above this level to further its core objectives.

The designated reserves on the balance sheet continue to differentiate free funds from those invested in fixed assets or committed to other specific projects. However, designated reserves represent free reserves that have been allocated for a specific use by the Board and can be reallocated at their discretion. This differentiates them from restricted reserves that have been received for a specific purpose and can only be used to deliver that objective.

c. Financial statements

The financial statements for the year end for 2022/23 show an income of £1,524,848 and expenditure of £1,673,217, decreasing reserves by £148,369.

The charity's income was below budget due to several factors. Grant Income was over £27K below budget Individual giving nearly £7K. It was initially thought that the campaign sent out by social media would raise awareness and increase direct debits by a higher level.

Additional grant income was secured, though with thanks to Garfield Weston, Pilkington Trust and Novartis, but this was well below budget forecast despite many high-quality applications to Trusts and Foundations. Recorded Grant funding in 2022 is higher, with some receipts in early 2022 relating to projects taking place in 2022/3.

On a positive note, costs were well controlled during the year and overheads were over £185,000 below budget albeit this is mainly savings on vacant posts.

The trading subsidiary, Allergy Research Limited (ARL), profit at year end was £799,908. The forecasting had been very conservative due to the unknown impact of the pandemic and global economy. These risks and challenges continue and therefore the budget forecasted for 2023/24 has also aimed to be conservative.

The new credit control process has already shown good results with debts over 3 months old being reduced. This process continues and ARL Debtors had been reduced to just over £75K in early September.

d. Principal risks and uncertainties

A strategic risk register is maintained continuously and reported at every charity and trading subsidiary board meeting and more often if needed, with planned mitigation activities and progress on these. The impact from post Covid-19 and global economic challenges carried forward into 2022/23.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Economic climate and cost of living

The economic climate and cost of living increases are continuing to affect everyone, including charities. We are privileged to have many fantastic supporters who donate and raise funds for our cause, but we have seen some cancellations of regular direct debits. It is very difficult to raise funds for allergy through grants from Trusts and Foundations, mainly we believe because the impact of living with allergy is still not understood. In 2022/23 we have applied for over £500k of grants but have been unsuccessful except for two small grants. We would like to offer our appreciation to Garfield Weston and the Pilkington Trust Foundation who have both provided small grants to our charity during this financial period.

We have also experienced increases in the costs of goods and services. In today's environment all charities must have IT systems and programmes to be able to function in the modern workplace, comply with required legislation and ensure the safety of data. The costs in this field have been increasing considerably.

Alongside this, salaries have increased across many sectors and recruitment during 2022/23 was extremely expensive and time consuming, due to recruitment agency costs and employee expectations on salaries. BAF has always benchmarked salaries well, but for a small charity to be able to recruit experienced staff we have had to raise salary levels. This has an on-going impact on finances at a time when it is even more difficult to raise funds through usual fundraising and trading activities.

ARL has seen a change in the type of business being contracted, which is as a direct result of economic pressures faced by companies who seek our endorsement services. We have also found that many of our corporate partners, who support us through grants and sponsorship, have reduced the amount of funding available. Many of these companies have also changed their funding timeframes and in January 2023 this did raise a risk on cashflow for a very short period. Our main contingency funds are usually held in a one-year fixed term account so we had funds but could not access them immediately. We review the amount held in fixed term accounts every year and for 2023/24 and this cashflow query will inform decisions we make for the future year.

Finance and Audit

We faced a huge challenge in 2022 as the recruitment of a Finance Business Manager with the right skills and experience for the salary we could offer took nearly a year. In that period, we contracted an external finance agency, Oculus, who were very supportive and provided the assurance of maintaining required financial management for almost ten months. This was extremely costly, but unavoidable, and meant that a lot of finance tasks became the remit of the CEO and Operations Director.

As an additional challenge, we had planned to change our finance system from 1st April 2022 and the move from SAGE to XERO was interesting. We are pleased to advise that all challenges were overcome, but the complexity of moving from one system to another came at a time when we had appointed new auditors. Kreston Reeves were incredibly supportive, and we would like to thank our auditors for their patience whilst they undertook a 'deep dive' of the charity and the trading subsidiary during the audit process. The challenges outlined did delay the final audit being signed off by Trustees and Directors, which took place in November 2022 when usually this takes place in September 2022. However, we still submitted all required documentation to the Charity Commission and Companies House, and Office of the Scottish Charity Regulator, on time. We appointed to the Finance Business Manager post in November 2022 and the XERO system has been in place for a whole financial year, enabling the audit for 2022/23 to run more smoothly.

Recruitment Challenges

The post-pandemic period has been a challenge as we found some long-term staff made decisions to retire or leave, so we had a need to recruit staff to key posts in 2022. We were successful in covering posts for our fundraising, communications, public affairs, helpline, project management, youth and volunteer engagement, food safety awareness and finance. However, the timeframes for recruiting some of these posts were considerable. This impacted on agency costs for recruitment as well as contracting external consultants to cover key roles, such as finance. It also meant that a lot of additional tasks fell to the CEO and Operations Director to ensure required activities moved forward. We have also had a couple of these posts become vacant again and are currently not recruiting for these posts as we take a risk assessment approach to the continued uncertainty of income during 2023/24.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Albeit initially we had found the return to office working and hybrid working did not have too many challenges, we found that on-boarding of new staff into a team working format was challenging post-Covid, where many if not all had worked remotely for a long period of time and found re-connecting to an office environment quite difficult. We have worked hard in 2022/23 to support staff embedding into the charity and trading subsidiary, and provided staff surveys for feedback, as well as additional support through well-being activities. We have introduced hybrid working arrangements, which has created connective challenges of its own for cross-team development and awareness of others' roles and responsibilities. We held an Away Day for all staff in July 2022, facilitated by an external coaching expert with the aim to bring staff together to share an understanding of each other's areas of work and expertise, a connection with the charity's values and objectives, and for the teams to get to know each other more. In January 2023 we held an all-day activity where teams shared their experiences and expertise with each other. All managers met off-site on a second day to discuss the outcomes of a Belbin team exercise, and to develop their shared approach to the delivery of key objectives for the year ahead.

Lease and Office Move

Another unforeseen challenge has been our landlord asking us to surrender our lease more than five years early due to their desire to change the use of the building, which post-pandemic have lots of vacant office space. These discussions commenced in early 2022 and are only just being finalised, with an office move by the end of June 2023. There have been negotiations to try to cover unforeseen costs but there are many aspects to consider when moving a company address and this has added to other challenges and change management for the charity. We have engaged staff in all aspects of the move, including a staff survey to ascertain thoughts on office space, to try to reduce the impact major change can have on employees. We have ensured the new premises are in a location which is easier to travel to for a majority of staff.

Succession Planning for a new CEO

Our CEO advised the Trustees and Directors in 2022 that due to health and personal reasons, they were looking to step down after eight years in the role. The CEO provided an extended notice period with a leaving date of 31st July 2023, which has provided the charity and trading subsidiary time to develop a succession plan. The Trustees would like to thank the CEO for their commitment to the charity, and also thank the Operations Director, who is stepping in as interim CEO until a new CEO is recruited. Recruitment commenced in the first quarter of this financial year and Trustees hope to make an announcement of the new incoming CEO in the near future. It is a challenge when any employee leaves, but the CEO has many responsibilities to handover both internally and externally. It is also a change for the organisation to adapt to, but Trustees are certain a new CEO will be able to build upon the charity's successful achievements when led by the outgoing CEO and ensure the charity continues to provide the best possible support and services for the allergic community into the future.

Sustained income generation

The principal financial risks faced by the Charity lie in the performance of the trading subsidiary in delivering the expected levels of profit as the charity remains reliant on the trading subsidiary donation for a majority of its income to cover charitable costs. Alongside the risks of reduced donations, inability to secure grant funding and/or a reduction in corporate partner engagement with our projects, we also have delays to new training schemes we had hope to launch in 2022/23 due to recruitment challenges. The key skills required to deliver this training are being considered and we are hopeful that the training will be launched by the end of 2023/24.

Our 3-to-5-year forecasts highlight the need for increased income streams to provide stability for the Charity and assist us in avoiding a repeat of the need to major restructure staffing levels. Our trading subsidiary is developing a marketing plan with ideas for income generation and the charity's expenditure is being closely monitored.

Financial forecasts suggest that the Charity remains able to fund operating costs over the next few years, however, this remains an area of continuous challenge for the Charity, especially if it wishes to achieve its future strategic objectives. The investment in diversifying the Charity's income streams should reduce the potential impact of an individual stream being adversely affected but this is in a climate of resource challenges for many in the third sector, and the current impact and legacy of Covid-19 means this landscape will continue to remain demanding.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

These financial risks are monitored closely by the Chief Executive and Finance Business Manager on a daily basis, and the Board are provided with regular financial updates and forecasts to enable them to assess the Charity's financial position.

This is a proper reflection of the use of designated funds and the payment of liabilities included on the balance sheet at 31 March 2023. The cash resources have been placed on deposits ranging from instant access to 12-months fixed-term, in a manner that provides for the funds to be available should they be required. In this way we seek to maximise the interest earned from prudent investments while maintaining the accessibility of these resources.

Structure, governance and management

a. Constitution

The organisation is a charitable company limited by guarantee, incorporated in August 2002 having been first registered as an unincorporated charity in 1991. The company was established under a Memorandum of Association which states the objects and powers of the charitable company and is governed under its Articles of Association. In addition to the Memorandum and Articles of Association the charity also operates under the Code of Good Governance approved by the National Council of Voluntary Organisations and the Charity Commission.

b. Methods of appointment or election of Trustees

A maximum of 12 Trustees can be appointed and there are currently ten on the Board, as of June 2023. The Trustees meet at least four times a year at board meetings, with an Annual General Meeting usually held in September. However, in 2022 the Annual General Meeting was held in November. This was because of the final audit reports being slightly delayed. During 2022 most meetings were adapted to a hybrid of in-person and on-line, as permitted under Article 47 of our governing document.

The Board of Trustees is responsible for the strategic direction of the Charity and its policy. The Chief Executive (CEO), and appropriate members of the Executive team, attend the Board meetings as required but have no voting rights.

The directors of the company are also the charity Trustees for the purposes of charity law and serve for a period of three years but may be re-elected for further periods of three years, up to a 10-year period. Our Trustee, James Redding stepped down in September 2022 after serving seven years on the Board. The Board would like to say a huge thank-you to James for his commitment and contribution over this term.

We also welcomed Peter Frampton as a new trustee with HR Consultancy expertise, who was appointed in September 2022, and two further Trustees who joined in November 2022. Dr. Stephanie Kayode is an adult allergy consultant at Guy's Hospital, which is the largest adult allergy department in the UK and is internationally accredited, and Elizabeth Withers, a policy, and public affairs professional experienced in supporting the voluntary and public sector and is based in Wales.

The Trustees have the power to appoint any person to be a Trustee who may have a required skillset or expertise. By the nature of the work that the charity carries out, medical and business knowledge is required on the Board of Trustees, and this is well represented on the present board.

Trustees regularly review the skills within the Board against a desired list of skills, and this informed recruitment of Trustees which took place during 2022 and 2023. The skills and expertise of the Trustees are used appropriately to steer the charity and to support the CEO as and when required. We have been privileged to have such new expertise on the Board of Trustees, and during 2023/24 recruitment is continuing. In September 2023 three of the Trustees will have completed the full 10 years permitted and therefore the Board is fully prepared for sustainability of the governance of the charity.

Among the many excellent applications received, the charity's trading subsidiary, Allergy Research Limited has also been able to recruit a new Director, Deborah Dixon, who joined the ARL Board in November 2022. Deborah brings Director level experience in medical health publishing and charity sector executive roles.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Structure, governance and management (continued)

c. Organisational structure and decision-making policies

Allergy UK has a Chief Executive (CEO) who supports the Board in delivering the organisation's strategic objectives. The CEO has delegated powers of responsibility for the resources of the Charity and directs the day-to-day operations of Allergy UK.

In February 2023, the CEO for the last eight years, Carla Jones, advised of their intention to resign with the last working day of 31st July 2023. As CEO she also acted as the Company Secretary to the Charity and was a Director of the trading company but in the interim period whilst the charity recruits a new CEO, the Board of Trustees and Board of ARL have made interim decisions whereby the Company Secretary responsibilities are transferred to the Finance Business Manager. Also, as there are four ARL Directors remaining then this role was not to be replaced at this time. The current Operations Director has taken on the responsibilities of interim CEO during the recruitment of a new CEO. Recruitment took place during March to May 2023 and the Board will be announcing the successful candidate in the near future.

The Board would like to thank the outgoing CEO for her contribution to the growth and development of the charity over the last eight years.

The Executive team, which includes an Operations Director, a Finance Business Manager and a Head of Clinical, provide subject matter expertise and support the CEO in directing and delivering the operations of the charity and trading subsidiary. The Executive team oversees the Operational Management team who are responsible for the delivery of service area activities focused on achieving our objectives through clinical, communications, endorsements, fundraising and helpline. We also have team members with expertise in project management and data management, supporting the charity with coordinating projects supported through grants and sponsorship and the development of our customer relationship management system and data management.

We have a Senior HR and Facilities Officer to provide personnel, health and safety and well-being functions. Payroll and IT support is outsourced.

d. Policies adopted for the induction and training of Trustees

New Trustees are provided with a recruitment pack which provides detailed information on the work of the Charity, the Memorandum and Articles of Association, the Charity Good Governance Code, which sets the principles and recommended practice for good governance, trustee job description and responsibilities and the last published accounts. An induction period is arranged for new Trustees to familiarise themselves with the charity's work, by coming to the office and meeting all the staff carrying out the various activities of the Charity, and the recently appointed Trustees visited Planwell House in May 2023.

e. Pay policy for key management personnel

The Trustees consider the Board of Trustees and the Chief Executive as key management personnel of the Charity. No remuneration was paid to the Trustees in the year except for relevant expenses.

The pay of the Charity's Chief Executive is reviewed annually by the Board of Trustees and benchmarked with charities of similar size. The Board acknowledged that the Chief Executive's pay in line with benchmark position and awarded an increase to reflect this.

f. Salary remuneration for staff

All salaries are benchmarked and reviewed each year. In May 2023 the Trustees received a proposal from the Executive team which was discussed and in June 2023 approved a pay increase of 3% for employees, back dated to April 1st 2023, with some adjustments depending on length of service under one year. There were also two posts which received increased salaries due to benchmarking and performance.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Structure, governance and management (continued)

g. Allergy UK staff training

All staff complete mandatory training for compliance with safeguarding and health and safety legislation. This includes First Aider, and Fire Marshall training. In addition, our clinical team deliver in-house training for all staff on allergic disease, to take all staff through a journey of understanding on the breadth of allergy, what it is and how the immune system's immunoglobulin E is influencing allergic reactions. This in-house training covers atopic eczema, allergic rhinitis, allergic asthma, food allergy, eye allergy and anaphylaxis and other additional education identified.

In 2022 all staff completed the mandatory on-line training, which included health and safety, fire safety awareness, Equality & Diversity, safe-guarding, cyber-security, resilience and time management training. Senior staff, such as managers, also completed stress awareness, mental health awareness, conflict management, communication skills, unconscious bias, health and well-being, and a leadership and management course. Two staff volunteered in 2022 to become Mental Health Aiders and attended courses to develop this internal support for the wider team if required by individual staff. However, both staff have since left and further training has been sought for the Senior Human Resource Officer.

Individual staff also have an annual appraisal, with regular one-to-ones with their line managers and identified training needs included in personal development plans to ensure the charity and its trading subsidiary are supported by skilled and experienced team members.

h. President and Vice-President

Our President, Professor P. Howarth is a founder Member of our Charity. He was a Professor of Allergy and Respiratory Medicine and Honorary Consultant Physician within Medicine at the University of Southampton and is an internationally known expert who has been involved in supporting the allergic community throughout his careers, including through his roles as a previous Trustee and Ambassador for Allergy UK. We are extremely grateful for his support over the last three decades.

Currently we have no Vice-President.

Plans for future periods

During the next 12 months we will continue working on the objectives outlined in our current strategy 2020-2025 with a sustained focus on:

- Continued monitoring of the economic situation and the effect this has on the Charity's income streams and other activities
- Empowerment of the voice of the allergic community through advocacy and our 'It's time to take allergy seriously' campaign and other public relations activities across the UK
- Expanding our supporter bases and ensuring we promote programmes that have a significant impact on the quality of life of the allergic community
- Broadening the work that we are doing with UK companies, as we continue to diversify our income generation activities through fundraising and our trading subsidiary activities
- Exploring new and innovative revenue-generating opportunities
- Continue developing our volunteer and youth engagement programmes
- In addition, we will be welcoming our new CEO and they will begin to consider the objectives for our 2025-2030 strategy.

The British Allergy Foundation
(A company limited by guarantee)

Trustees' report (continued)
For the year ended 31 March 2023

Statement of Trustees' responsibilities

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors


Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditors are aware of that information.

Auditors

The auditors, Kreston Reeves LLP, have indicated their willingness to continue in office. The designated Trustees will propose a motion reappointing the auditors at a meeting of the Trustees.

Approved by order of the members of the board of Trustees and signed on their behalf by:



Ms L Pritchard
Chair

Date: 28th September 2023

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation

Opinion

We have audited the financial statements of The British Allergy Foundation (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2023 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Charity balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2023 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a Strategic report.

Responsibilities of trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Capability of the audit in detecting irregularities, including fraud

Based on our understanding of the charity and the sector as a whole, and through discussion with the Trustees and other management (as required by auditing standards), we identified that the principal risks of non-compliance with laws and regulations related to health and safety and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Charities SORP (FRS 102) Second Edition (released October 2019), the Companies Act 2006, taxation and pension legislation. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to incorrect recognition of legacy income, posting inappropriate journal entries and management bias in accounting estimates and judgemental areas of the financial statements. Audit procedures performed by the engagement team included:

- Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud; and
- Assessment of identified fraud risk factors; and
- Review of expenditure to confirm no evidence of personal benefit; and
- Identifying and assessing the design effectiveness of controls that management has in place to prevent and detect fraud; and
- Challenging assumptions and judgements made by management in its significant accounting estimates; and
- Performing analytical procedures to identify any unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and
- Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business; and
- Reading minutes of meetings of those charged with governance; and
- Review of significant and unusual transactions and evaluation of the underlying financial rationale supporting the transactions; and
- Identifying and testing journal entries, in particular any manual entries made at the year end for financial statement preparation.

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The British Allergy Foundation
(A company limited by guarantee)

Independent auditors' report to the Members of The British Allergy Foundation (continued)

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, Part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Samantha Rouse FCCA DChA (Senior statutory auditor)

for and on behalf of
Kreston Reeves LLP

Chartered Accountants
Statutory Auditor

Canterbury

Date: **30 November 2023**

Kreston Reeves LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

The British Allergy Foundation
(A company limited by guarantee)

Consolidated Statement of financial activities (incorporating income and expenditure account)
For the year ended 31 March 2023

	Note	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:					
Donations and legacies	3	36,265	122,258	158,523	77,021
Charitable activities	4	22,410	-	22,410	2,237
Other trading activities	5	1,338,224	-	1,338,224	1,569,234
Investments	6	5,691	-	5,691	2,043
Total income		1,402,590	122,258	1,524,848	1,650,535
Expenditure on:					
Raising funds	7	255,682	31,290	286,972	458,317
Charitable activities	8	1,386,245	-	1,386,245	1,245,885
Total expenditure		1,641,927	31,290	1,673,217	1,704,202
Net movement in funds		(239,337)	90,968	(148,369)	(53,667)
Reconciliation of funds:					
Total funds brought forward		1,100,610	15,089	1,115,699	1,169,366
Net movement in funds		(239,337)	90,968	(148,369)	(53,667)
Total funds carried forward		861,273	106,057	967,330	1,115,699

The Consolidated statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 14 to 36 form part of these financial statements.

The British Allergy Foundation
(A company limited by guarantee)
Registered number: 04509293

Consolidated balance sheet
As at 31 March 2023

	Note	2023 £	2022 £
Fixed assets			
Intangible assets	13	92,521	130,517
Tangible assets	14	17,227	27,431
Investments	15	14	14
		<u>109,762</u>	<u>157,962</u>
Current assets			
Stocks	16	961	761
Debtors	17	294,920	388,254
Investments	18	462,249	460,000
Cash at bank and in hand		520,896	846,276
		<u>1,279,026</u>	<u>1,695,291</u>
Creditors: amounts falling due within one year	19	(421,458)	(737,554)
Net current assets		<u>857,568</u>	<u>957,737</u>
Total net assets		<u><u>967,330</u></u>	<u><u>1,115,699</u></u>
Charity funds			
Restricted funds	20	106,057	15,089
Unrestricted funds	20	861,273	1,100,610
Total funds		<u><u>967,330</u></u>	<u><u>1,115,699</u></u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



Ms L Pritchard
Chair

Date: 28 Sept 2023

The notes on pages 24 to 50 form part of these financial statements.

The British Allergy Foundation
(A company limited by guarantee)
Registered number: 04509293

Charity balance sheet
As at 31 March 2023

	Note	2023 £	2022 £
Fixed assets			
Intangible assets	13	92,521	128,226
Tangible assets	14	17,037	26,719
Investments	15	16	16
		<u>109,574</u>	<u>154,961</u>
Current assets			
Stocks	16	961	761
Debtors	17	211,051	381,879
Investments	18	462,249	460,000
Cash at bank and in hand		260,287	283,097
		<u>934,548</u>	<u>1,125,737</u>
Creditors: amounts falling due within one year	19	(93,623)	(186,180)
Net current assets		<u>840,925</u>	<u>939,557</u>
Total net assets		<u><u>950,499</u></u>	<u><u>1,094,518</u></u>
Charity funds			
Restricted funds	20	106,057	15,089
Unrestricted funds	20	844,442	1,079,429
Total funds		<u><u>950,499</u></u>	<u><u>1,094,518</u></u>

The Charity's net movement in funds for the year was £(124,331) (2022 - £(53,667)).

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



Ms L Pritchard

Date: 28 Sep 2023

The notes on pages 24 to 50 form part of these financial statements.

The British Allergy Foundation
(A company limited by guarantee)

Consolidated statement of cash flows
For the year ended 31 March 2023

	Note	2023 £	2022 £
Cash flows from operating activities			
Net cash (used in)/provided by operating activities	23	<u>(327,071)</u>	<u>(27,363)</u>
Cash flows from investing activities			
Interest received		5,691	2,025
Purchase of intangible assets		(550)	(23,759)
Purchase of tangible fixed assets		(1,201)	(13,114)
Purchase of investments		-	(4)
Decrease/(increase) in short term deposit accounts		<u>(2,249)</u>	<u>393,098</u>
Net cash provided by investing activities		<u>1,691</u>	<u>358,246</u>
Change in cash and cash equivalents in the year		(325,380)	330,883
Cash and cash equivalents at the beginning of the year		<u>846,276</u>	<u>515,393</u>
Cash and cash equivalents at the end of the year	24	<u>520,896</u>	<u>846,276</u>

The notes on pages 24 to 50 form part of these financial statements

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

1. General information

The British Allergy Foundation is a charitable private company limited by guarantee, incorporated in England, Wales and Scotland. The liability of each member in the event of a winding up is limited to £1. The registered office is London House Business Centre, Thames Road, Crayford, Dartford, England, DA1 4SL.

The principal activity of the Charity is to increase awareness of allergy and causes of anaphylaxis through services, advocacy, campaigns for policy and legislation changes, education on management and prevention of allergy, supporting the allergic community, promoting research into causes of allergy and improving quality of life, advocacy, advice, support and information services.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The British Allergy Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated statement of financial activities (SOFA) and Consolidated balance sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The Charity has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of financial activities in these financial statements.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

2. Accounting policies (continued)

2.2 Income

All income is recognised once the Charity has entitlement to the income, after any performance conditions have been met, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Incoming resources from charitable trading activities are recognised as follows:

The sale of goods - revenue is recognised when donated goods are sold;

The rendering of services - revenue is recognised as follows:

Applications for the seal of approval when the application has been signed and the terms agreed;

Renewal of the seal of approval in the month of commencement of the new period; and

Services, such as training, in the month the services are supplied.

Voluntary income is received by way of grants, donations, legacies and gifts and is included in full in the Statement of Financial Activities when receivable. Grants, where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Incoming resources from grants, where related to performance and specific deliverables, are accounted for as the charity earns the right to consideration by its performance.

Investment income is included when receivable.

Legacies are included when the Charity has legal entitlement, the amount can be measured reliably and it is probable that the income will be received.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.3 Expenditure

Resources expended are included in the Statement of Financial Activities on an accrual basis and have been classified under headings that aggregate all costs related to the category inclusive of any VAT which cannot be recovered. Expenditure is recognised where there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Fundraising costs are those incurred in seeking voluntary contributions and the staging of fundraising events.

Support costs

Support costs are those costs incurred directly in support of expenditure on the objects of the company.

2.4 Government grants

Income from government grants is included at the point of application for the funds if that funding is considered to meet the criteria of measurability, reliability and probability. Otherwise it is accounted for upon receipt.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

2. Accounting policies (continued)

2.5 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated statement of financial activities.

2.6 Intangible assets and amortisation

Intangible assets costing £1,000 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its expected useful life.

Amortisation is provided on the following bases:

Website	-	10 % straight line
CRM Development costs	-	10 % straight line

2.7 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis. All new fixed assets purchased in 2022/23 and subsequently are depreciated on a straight-line basis.

Depreciation is provided on the following basis:

Furniture and fittings	-	25% reducing balance
Computer & office equipment	-	25% reducing balance

2.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Consolidated statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

2. Accounting policies (continued)

2.9 Stocks

Stocks are valued at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated statement of financial activities as a finance cost.

2.13 Financial instruments

The Group only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight-line basis over the lease term.

2.15 Pensions

The Group operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Group to the fund in respect of the year.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Donations	36,265	-	36,265
Grants	-	122,258	122,258
	<u>36,265</u>	<u>122,258</u>	<u>158,523</u>

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Donations	34,977	-	34,977
Legacies	16,375	-	16,375
Grants	11,000	14,669	25,669
	<u>62,352</u>	<u>14,669</u>	<u>77,021</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

4. Income from charitable activities

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Sale of translation cards	22,005	22,005	1,982
Affiliate marketing	-	-	5
Fees received	405	405	250
	<u>22,410</u>	<u>22,410</u>	<u>2,237</u>

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Fundraising events	20,918	20,918	20,298

Income from trading subsidiary

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Seal of approval	357,815	357,815	479,602
Renewals	689,894	689,894	642,675
Allergy Friendly Products	60,700	60,700	61,650
Corporate partners	205,000	205,000	355,819
Alerts	3,120	3,120	3,725
Allergy Awareness Scheme	777	777	5,465
	<u>1,317,306</u>	<u>1,317,306</u>	<u>1,548,936</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

6. Investment income

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Interest received	5,691	5,691	2,043

7. Expenditure on raising funds

Costs of raising voluntary income

	Unrestricted funds 2023 £	Total funds 2023 £
Direct costs	2,178	2,178
Professional fees	2,653	2,653
	<u>4,831</u>	<u>4,831</u>

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Direct costs	8,845	60,319	69,164
Professional fees	5,425	-	5,425
	<u>14,270</u>	<u>60,319</u>	<u>74,589</u>

Fundraising trading expenses

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Fundraising expenses	9,132	31,290	40,422

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

7. Expenditure on raising funds (continued)

Fundraising trading expenses (continued)

	Unrestricted funds 2022 £	Total funds 2022 £
Fundraising expenses	30,396	30,396

Expenditure on trading subsidiary

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Cost of sales	241,719	241,719	353,332

8. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2023 £	Total 2023 £
Charitable activities	1,386,245	1,386,245

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Charitable activities	1,244,055	1,830	1,245,885

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

9. Analysis of expenditure by activities

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Charitable activities	1,024,622	361,623	1,386,245

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £
Charitable activities	878,440	367,445	1,245,885

Analysis of direct costs

	Total funds 2023 £	Total funds 2022 £
Staff costs	877,828	757,225
Communications	127,360	101,521
Other direct costs	19,434	19,694
	1,024,622	878,440

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

9. Analysis of expenditure by activities (continued)

Analysis of support costs

	Total funds 2023 £	Total funds 2022 £
Premises	117,758	140,063
Communications	5,292	3,261
Legal & professional	32,889	50,079
General office expenses	111,753	119,679
Depreciation	27,450	27,779
Financial charges	31,506	13,122
Governance costs	34,975	12,250
Trustee meetings	-	1,212
	361,623	367,445

10. Auditors' remuneration

The auditors' remuneration amounts to an auditor fee of £10,350 (2022 - £8,500), and remuneration in relation to the preparation of the financial statements and corporation tax returns of £4,125 (2022 - £3,750).

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

11. Staff costs

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Wages and salaries	783,375	670,528	783,375	670,528
Social security costs	74,217	62,979	74,217	62,979
Contribution to defined contribution pension schemes	20,236	23,718	20,236	23,718
	<u>877,828</u>	<u>757,225</u>	<u>877,828</u>	<u>757,225</u>

Two ex-gratia payments were made with regards to settlement agreements made by the charity (2022: None). The charity felt it had a moral obligation to make these payments in recognition of the individuals' contribution to the charity. These ex-gratia payments totalled £8,940, one of which was accrued at the year end with a balance of £3,500 (2022: £Nil).

The average number of persons employed by the Charity during the year was as follows:

	Group 2023 No.	Group 2022 No.	Charity 2023 No.	Charity 2022 No.
Headcount	26	23	26	23

The average headcount expressed as full-time equivalents was:

	Group 2023 No.	Group 2022 No.	Charity 2023 No.	Charity 2022 No.
Charitable activities	19	12	19	12
Generating funds	3	7	3	7
	<u>22</u>	<u>19</u>	<u>22</u>	<u>19</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group 2023 No.	Group 2022 No.
In the band £60,001 - £70,000	2	1
In the band £70,001 - £80,000	-	1

The key management personnel of the group comprise the Board of Trustees, the Chief Executive and Operations Director (prior year only the Trustees and Chief Executive). The total employee benefits of the key management personnel of the group were £149,328 (2022 - £84,069).

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

12. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 31 March 2023, expenses totalling £2,823 were reimbursed or paid directly to 5 Trustees (2022 - 2 Trustees received a total of £1,178). These related to travel and hotel costs to attend Board meetings.

13. Intangible assets

Group

	Website £	CRM Development Costs £	Total £
Cost			
At 1 April 2022	107,102	150,562	257,664
Additions	550	-	550
Disposals	(32,721)	(5,918)	(38,639)
At 31 March 2023	74,931	144,644	219,575
Amortisation			
At 1 April 2022	64,173	62,974	127,147
Charge for the year	5,983	15,056	21,039
At 31 March 2023	51,210	75,844	127,054
Net book value			
At 31 March 2023	23,721	68,800	92,521
At 31 March 2022	42,929	87,588	130,517

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

13. Intangible assets (continued)

Charity

	Website £	CRM Development Costs £	Total £
Cost			
At 1 April 2022	102,546	150,562	253,108
Additions	550	-	550
Disposals	(28,165)	(5,918)	(34,083)
At 31 March 2023	<u>74,931</u>	<u>144,644</u>	<u>219,575</u>
Amortisation			
At 1 April 2022	61,908	62,974	124,882
Charge for the year	5,565	15,056	20,621
At 31 March 2023	<u>51,210</u>	<u>75,844</u>	<u>127,054</u>
Net book value			
At 31 March 2023	<u>23,721</u>	<u>68,800</u>	<u>92,521</u>
At 31 March 2022	<u>40,638</u>	<u>87,588</u>	<u>128,226</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

14. Tangible fixed assets

Group

	Furniture & fittings £	Computer & office equipment £	Total £
Cost or valuation			
At 1 April 2022	61,911	86,777	148,688
Additions	-	1,201	1,201
Disposals	(47,456)	(34,407)	(81,863)
At 31 March 2023	<u>14,455</u>	<u>53,571</u>	<u>68,026</u>
Depreciation			
At 1 April 2022	48,992	72,265	121,257
Charge for the year	3,160	3,829	6,989
On disposals	(45,318)	(32,129)	(77,447)
At 31 March 2023	<u>6,834</u>	<u>43,965</u>	<u>50,799</u>
Net book value			
At 31 March 2023	<u>7,621</u>	<u>9,606</u>	<u>17,227</u>
At 31 March 2022	<u>12,919</u>	<u>14,512</u>	<u>27,431</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

14. Tangible fixed assets (continued)

Charity

	Furniture & fittings £	Computer & office equipment £	Total £
Cost or valuation			
At 1 April 2022	61,911	71,720	133,631
Additions	-	1,201	1,201
Disposals	(47,456)	(22,013)	(69,469)
At 31 March 2023	14,455	50,908	65,363
Depreciation			
At 1 April 2022	48,992	57,920	106,912
Charge for the year	3,160	3,670	6,830
On disposals	(45,318)	(20,098)	(65,416)
At 31 March 2023	6,834	41,492	48,326
Net book value			
At 31 March 2023	7,621	9,416	17,037
At 31 March 2022	12,919	13,800	26,719

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

15. Fixed asset investments

	Investments in subsidiary companies £
Group	
Cost or valuation	
At 1 April 2022	14
At 31 March 2023	<u>14</u>
	Investments in subsidiary companies £
Charity	
Cost or valuation	
At 1 April 2022	16
At 31 March 2023	<u>16</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

15. Fixed asset investments (continued)

Principal subsidiaries

The following were subsidiary undertakings of the Charity:

Names	Company number	Registered office or principal place of business	Class of shares	Holding Included in consolidation
Allergy Research Ltd	03550847	Planwell House Lefa Business Park, Edgington Way, Sidcup, Kent, DA14 5BH	Ordinary	100% Yes
Allergy UK Ltd (Dormant)	06302734	Planwell House Lefa Business Park, Edgington Way, Sidcup, Kent, DA14 5BH	Ordinary	100% No
Allergy Aware Scheme Ltd (Dormant)	06300759	Planwell House Lefa Business Park, Edgington Way, Sidcup, Kent, DA14 5BH	Ordinary	100% No
Allergy England Ltd (Dormant)	08494679	Planwell House Lefa Business Park, Edgington Way, Sidcup, Kent, DA14 5BH	Ordinary	100% No
Allergy Scotland Ltd (Dormant)	SC447980	272 Bath Street, Glasgow, G2 4JR	Ordinary	100% No
Allergy Europe Ltd (Dormant)	08695950	Planwell House Lefa Business Park, Edgington Way, Sidcup, Kent, DA14 5BH	Ordinary	100% No
Allergy Northern Ireland Ltd (Dormant)	NI679729	58, Antrim Enterprise Agency, Unit 19 Greystone Road, Antrim, County Antrim, Northern Ireland, BT41 1JZ	Ordinary	100% No
Allergy Wales Ltd (Dormant)	13459606	International House, 10 Churchill Way, Cardiff, United Kingdom, CF10 2HE	Ordinary	100% No

The financial results of the subsidiaries for the year were:

Names	Income £	Expenditure £	Net assets £
Allergy Research Ltd	1,317,589	(1,317,589)	21,183
Allergy UK Ltd (Dormant)	-	-	2
Allergy Aware Scheme Ltd (Dormant)	-	-	2
Allergy England Ltd (Dormant)	-	-	2
Allergy Scotland Ltd (Dormant)	-	-	2
Allergy Europe Ltd (Dormant)	-	-	2
Allergy Northern Ireland Ltd (Dormant)	-	-	2
Allergy Wales Ltd (Dormant)	-	-	2

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

16. Stocks

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Goods for resale	961	761	961	761

17. Debtors

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Due within one year				
Trade debtors	214,822	308,929	-	40,993
Amounts owed by group undertakings	-	-	137,442	270,606
Other debtors	14,951	7,470	8,462	2,175
Prepayments and accrued income	65,147	71,855	65,147	68,105
	294,920	388,254	211,051	381,879

18. Current asset investments

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Short term deposits	462,249	460,000	462,249	460,000

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

19. Creditors: Amounts falling due within one year

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Trade creditors	78,215	119,228	44,615	23,794
Other taxation and social security	19,016	61,711	19,016	22,822
Other creditors	1,988	985	1,988	985
Accruals and deferred income	322,239	555,630	28,004	138,579
	421,458	737,554	93,623	186,180
	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Deferred income at 1 April 2023	92,964	-	18,024	-
Resources deferred during the year	194,024	408,184	12,500	96,899
Amounts released from previous periods	(92,964)	(315,220)	(18,024)	(78,875)
Deferred income at 31 March 2023	194,024	92,964	12,500	18,024

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

20. Statement of funds

Statement of funds - current year

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
Unrestricted funds					
Designated funds					
Awareness Campaign Reserve	5,120	-	(5,120)	-	-
Resource Building Reserve	100,291	-	(100,291)	-	-
IT Reserve	10,000	-	(10,000)	-	-
Fundraising Reserve	42,562	-	(42,562)	-	-
Fixed Asset Fund	26,720	-	(6,830)	(2,853)	17,037
Contingency Fund	466,220	-	-	-	466,220
Project Delivery Reserve	75,000	-	(75,000)	-	-
Public Affairs Campaign Reserve	16,395	-	-	-	16,395
Digital Media Reserve	14,795	-	(8,340)	-	6,455
	757,103	-	(248,143)	(2,853)	506,107
	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
General funds					
General Free Reserve	322,326	1,402,590	(1,393,784)	2,853	333,985
Allergy Research Limited	21,181	-	-	-	21,181
	343,507	1,402,590	(1,393,784)	2,853	355,166
Total Unrestricted funds	1,100,610	1,402,590	(1,641,927)	-	861,273

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

20. Statement of funds (continued)

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
Restricted funds					
HCP Scotland Training Fund	420	-	-	-	420
Novartis	1,408	-	-	-	1,408
Global Skin	13,261	-	(13,261)	-	-
Sanofi Youth	-	77,583	-	-	77,583
Nutricia	-	4,680	-	-	4,680
Pfizer	-	9,466	-	-	9,466
Aimmune	-	5,529	(5,529)	-	-
Garfield Weston	-	25,000	(12,500)	-	12,500
	15,089	122,258	(31,290)	-	106,057
Total of funds	1,115,699	1,524,848	(1,673,217)	-	967,330

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

20. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 April 2021 £	As restated Income £	As restated Expenditure £	As restated Transfers in/out £	Balance at 31 March 2022 £
Unrestricted funds					
Designated funds					
Awareness Campaign Reserve	50,000	-	(44,880)	-	5,120
Resource Building Reserve	100,291	-	-	-	100,291
IT Reserve	10,000	-	-	-	10,000
Fundraising Reserve	50,000	-	(7,438)	-	42,562
Fixed Asset Fund	21,747	-	(8,142)	13,115	26,720
Contingency Fund	466,220	-	-	-	466,220
Project Delivery Reserve	75,000	-	-	-	75,000
Public Affairs Campaign Reserve	-	-	(33,605)	50,000	16,395
Digital Media Reserve	21,190	650	(6,636)	(409)	14,795
	<u>794,448</u>	<u>650</u>	<u>(100,701)</u>	<u>62,706</u>	<u>757,103</u>
	Balance at 1 April 2021 £	As restated Income £	As restated Expenditure £	As restated Transfers in/out £	Balance at 31 March 2022 £
General funds					
General Free Reserve	267,818	1,635,216	(1,541,352)	(39,356)	322,326
Allergy Research Limited	21,181	-	-	-	21,181
	<u>288,999</u>	<u>1,635,216</u>	<u>(1,541,352)</u>	<u>(39,356)</u>	<u>343,507</u>
Total Unrestricted funds	<u>1,083,447</u>	<u>1,635,866</u>	<u>(1,642,053)</u>	<u>23,350</u>	<u>1,100,610</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

20. Statement of funds (continued)

	Balance at 1 April 2021 £	As restated Income £	As restated Expenditure £	As restated Transfers in/out £	Balance at 31 March 2022 £
Restricted funds					
HCP Scotland Training Fund	600	-	(180)	-	420
Digital Media	25,000	-	(1,650)	(23,350)	-
Over The Wall - Camp in the Cloud	1,719	-	(1,719)	-	-
Research Project	58,600	-	(58,600)	-	-
Novartis	-	13,261	-	-	13,261
Global Skin	-	1,408	-	-	1,408
	<u>85,919</u>	<u>14,669</u>	<u>(62,149)</u>	<u>(23,350)</u>	<u>15,089</u>
Total of funds	<u>1,169,366</u>	<u>1,650,535</u>	<u>(1,704,202)</u>	<u>-</u>	<u>1,115,699</u>

The HCP (health care professional) Scotland Training Fund is to enable the charity to encourage training in allergy, by making grants to committed HCPs to meet a percentage of their training costs, at a time when the Health Service has reduced their funding in this area.

Novartis provided funding to create two webinars developed for healthcare professionals, particularly in primary care, to raise awareness of CSU as a disease not related to allergy, with authoritative guidance on management, including onward referral. Also to create an infographic to help present an understandable overview of the treatment and management of CSU. A leaflet to inform patients of management and care pathways to new targeted treatments. Offering helpful information for patients to support their engagement with their GP.

Global Skin made a grant for the review of Allergy UK's current eczema resources on Allergy UK's website and update where needed. A podcast on living with eczema with a target database, along with a funds for a Facebook add for World Eczema Day.

Sanofi Youth is in relation to the Development of Youth Engagement with Allergy.

Nutricia is a Sponsorship to develop and deliver educational activities that are beneficial to the allergic community.

Aimmune aims to raise awareness with healthcare professionals of the impact of food allergy and the emerging pathways to prevent and manage this condition.

Garfield Weston is to help fund the operation of the Allergy helpline.

Pfizer fund is for producing a booklet on skin to skin, leaflet on Atopic Eczema and a leaflet on Eczema blood monitoring.

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

21. Summary of funds

Summary of funds - current year

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2023 £
Designated funds	757,103	-	(248,143)	(2,853)	506,107
General funds	343,507	1,402,590	(1,393,784)	2,853	355,166
Restricted funds	15,089	122,258	(31,290)	-	106,057
	<u>1,115,699</u>	<u>1,524,848</u>	<u>(1,673,217)</u>	<u>-</u>	<u>967,330</u>

Summary of funds - prior year

	Balance at 1 April 2021 £	As restated Income £	As restated Expenditure £	As restated Transfers in/out £	Balance at 31 March 2022 £
Designated funds	794,448	650	(100,701)	62,706	757,103
General funds	288,999	1,635,216	(1,541,352)	(39,356)	343,507
Restricted funds	85,919	14,669	(62,149)	(23,350)	15,089
	<u>1,169,366</u>	<u>1,650,535</u>	<u>(1,704,202)</u>	<u>-</u>	<u>1,115,699</u>

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

22. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Tangible fixed assets	17,227	-	17,227
Intangible fixed assets	92,521	-	92,521
Fixed asset investments	14	-	14
Current assets	1,172,969	106,057	1,279,026
Creditors due within one year	(421,458)	-	(421,458)
Total	861,273	106,057	967,330

Analysis of net assets between funds - prior year

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Tangible fixed assets	27,431	-	27,431
Intangible fixed assets	130,517	-	130,517
Fixed asset investments	14	-	14
Current assets	1,680,202	15,089	1,695,291
Creditors due within one year	(737,554)	-	(737,554)
Total	1,100,610	15,089	1,115,699

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

23. Reconciliation of net movement in funds to net cash flow from operating activities

	Group 2023 £	Group 2022 £
Net expenditure for the year (as per Statement of Financial Activities)	(148,369)	(53,667)
Adjustments for:		
Depreciation charges	6,989	8,379
Amortisation charges	21,039	20,093
Interest received	(5,691)	(2,025)
Profit on disposal of intangibles	17,507	-
Profit on disposal of fixed assets	4,416	-
Increase in stocks	(200)	(161)
Decrease/(increase) in debtors	93,334	(130,364)
(Decrease)/Increase in creditors	(316,096)	130,382
Net cash used in operating activities	(327,071)	(27,363)

24. Analysis of cash and cash equivalents

	Group 2023 £	Group 2022 £
Cash in hand	520,896	846,276

25. Analysis of changes in net debt

	At 1 April 2022 £	Cash flows £	At 31 March 2023 £
Cash at bank and in hand	846,276	(325,380)	520,896
Liquid investments	460,000	2,249	462,249
	1,306,276	(323,131)	983,145

The British Allergy Foundation
(A company limited by guarantee)

Notes to the financial statements
For the year ended 31 March 2023

26. Pension commitments

The Group operates a defined contribution pension scheme for its employees. The pension cost charge for the period represents contributions payable by the Charity to the scheme and amounted to £20,236 (2022 - £23,718). At the balance sheet date £Nil was recognised as a liability owed to the scheme (2022 - £Nil).

27. Operating lease commitments

At 31 March 2023 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Not later than 1 year	92,427	120,317	92,427	120,317
Later than 1 year and not later than 5 years	17,824	110,905	17,824	110,905
	110,251	231,222	110,251	231,222

28. Related party transactions

The charity has not entered into any related party transaction during the year (2022: £Nil), nor are there any outstanding balances owing between related parties and the Charity at 31 March 2023 (2022: £Nil).

29. Controlling party

There is no ultimate controlling party.